Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 250

Alzheimer’s Association International Conference 2019

Posted by fidest press agency su domenica, 14 luglio 2019

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, marks the end of the first half of 2019 with major milestones as it continues to expand its footprint in neurology and lead the digital biomarker revolution across healthcare. Most recently, on July 1, Quanterix announced it had closed its acquisition of UmanDiagnostics AB, a company widely recognized as the leading provider of antibodies to measure Nf-L.
Quanterix first announced its definitive agreement to acquire privately held Uman on June 26. Based in Umeå, Sweden, Uman has become the provider of choice for biopharmaceutical and diagnostic applications. The acquisition allows Quanterix to supply researchers globally with the “best-in-class” Simoa Nf-L assays, while continuing to innovate new digital biomarkers to advance the field of research in diagnostics for neurological disorders. The deal also positions Quanterix to capitalize on the growth fueled by the momentum in Nf-L as a tremendously promising brain biomarker. Publications citing the Simoa Nf-L assay have accelerated since the assay was launched in 2016 and totaled 172 as of the end of 2018, adding to nearly 400 publications on Uman’s Nf-L antibodies in Cerebrospinal Fluid (CSF).
The impact of Quanterix’ strategic investments and milestones as they specifically support Alzheimer’s research will be on full display at the Alzheimer’s Association International Conference (AAIC), the largest and most influential international meeting dedicated to dementia science, taking place July 14-18 in Los Angeles, Calif. On July 15, Hrusovsky will provide an update on Quanterix’ progress and plans for fueling neuro biomarker innovations and will moderate a panel discussion featuring several of the world’s foremost researchers in Alzheimer’s disease.
Earlier in June, the company re-engineered ultra-sensitivity with the launch of the Simoa HD-X Analyzer, its latest fully automated Simoa bead-based immunoassay instrument model. The HD-X is the next generation HD-1, launched in 2013, which first made Simoa’s ultrasensitive digital biomarker measurements available to researchers around the world and which has led to over 500 peer-reviewed publications. The ground-breaking HD-X leverages many decades of collective technical expertise and user experiences to deliver the “best-in-class” technological innovation into practical reality for researchers. The new flagship HD-X has been designed to deliver productivity improvements, greater user flexibility, unparalleled sensitivity, and “best-in-class” assay performance across a broad assay menu to empower biomarker research and accelerate drug development.


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: